IceCure Medical Reminds Rights Holders of Expiring Subscription Period for Rights Offering

Strategic Insights -

The subscription period for IceCure Medical's rights offering is set to expire at 5:00 PM Eastern Time on Monday, July 28, 2025. The rights offering, which aimed to raise funds for the company's minimally-invasive cryoablation technology, was announced earlier this month. The technology destroys tumors by freezing, providing a safe and effective alternative to surgical tumor removal. As of the record date, July 9, 2025, holders of IceCure Medical's ordinary shares received non-transferable subscription rights to purchase up to 10,000,000 units at a subscription price of $1.00 per unit.

Key Takeaways:

  • The rights offering subscription period is set to expire at 5:00 PM Eastern Time on Monday, July 28, 2025.
  • The company distributed non-transferable subscription rights to purchase up to 10,000,000 units at a subscription price of $1.00 per unit to all holders of ordinary shares as of July 9, 2025.
  • Each subscription right entitled the holder to purchase 0.1703 of a unit, comprised of one ordinary share and one warrant to purchase one ordinary share.
  • No fractional subscription rights were distributed, and no fractional units will be issued upon the exercise of any subscription rights.
  • The company may extend the period for exercising subscription rights.

Statistics:

  • 10,000,000 units are available for purchase at a subscription price of $1.00 per unit.
  • The record date for the rights offering was July 9, 2025.
  • The expected expiration date of the rights offering is July 28, 2025.
  • The company has engaged Maxim Group LLC as dealer-manager for the rights offering.

Sources:

  • (Nasdaq: ICMM) press release dated July 24, 2025.
  • IceCure Medical's Registration Statement on Form F-1 (File No. 333-288062) dated July 9, 2025.
  • U.S. Securities and Exchange Commission website: .
  • Broadridge Corporate Issuer Solutions, LLC, (855) 793-5068 (toll free in the U.S. and Canada) or +1 (720) 414-6898 (for calls outside the U.S. and Canada).